Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 20/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23587208 | 1.00 | ROCK2 (0.85) | ROCK2 | |
| SCHEMBL23382885 | 0.95 | ROCK2 (0.78) | ROCK2 | |
| SCHEMBL23382880 | 0.93 | ROCK2 (0.85) | ROCK2 | |
| SCHEMBL23382339 | 0.92 | ROCK2 (0.85) | ROCK2 | |
| SCHEMBL23382887 | 0.92 | ROCK2 (0.85) | ROCK2 | |
| SCHEMBL23683865 | 0.92 | ROCK2 (1.00) | ROCK2 | |
| SCHEMBL23382605 | 0.91 | ROCK2 (0.86) | ROCK2 | |
| SCHEMBL23382914 | 0.91 | ROCK2 (0.84) | ROCK2 | |
| SCHEMBL20653934 | 0.90 | ROCK2 (0.70) | ROCK2 | |
| SCHEMBL23732315 | 0.89 | ROCK2 (0.85) | ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11673886-B2 | 5-membered and bicyclic heterocyclic amides as inhibitors of ROCK | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-06-13 | — | — | US | disclosed |
| US-11078197-B2 | 5-membered and bicyclic heterocyclic amides as inhibitors of rock | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-08-03 | — | — | US | disclosed |
| EP-3652168-B1 | 5-MEMBERED AND BICYCLIC HETEROCYCLIC AMIDES AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2021-06-30 | — | — | EP | disclosed |
| US-20210147406-A1 | 5-MEMBERED AND BICYCLIC HETEROCYCLIC AMIDES AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2021-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11673886-B2 | 5-membered and bicyclic heterocyclic amides as inhibitors of ROCK | MYLK, ROCK1, ROCK2 | ROCK2 3/4885 |
| US-20210147406-A1 | 5-MEMBERED AND BICYCLIC HETEROCYCLIC AMIDES AS INHIBITORS OF ROCK | MYLK, ROCK1, ROCK2 | ROCK2 3/4885 |
| US-11078197-B2 | 5-membered and bicyclic heterocyclic amides as inhibitors of rock | MYLK, ROCK1, ROCK2 | ROCK2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.